



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Supplemental Information Disclosure Statement)	ATTORNEY DOCKET NO.	601-1-077DIV1
	SERIAL NO.	10/643,233
	APPLICANT	Peter Lobel, et al.
	FILING DATE	August 18, 2003
	GROUP	1632

U.S. PATENT DOCUMENTS

EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AS	AH	B. L. Davidson, et al., Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system, Proc. Natl. Acad. Sci., 97:3428-3432 (2000)
	AI	X. Xiao, et al., Gene transfer by adeno-associated virus vectors into the central nervous system, Exp. Neurol, 144:113-24 (1997) Abstract
	AJ	K.R. Clark, et al., Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression, J Drug Target, 7:269-83 (1999) Abstract
	AK	M.A. Passini, et al., Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis, The Journal of Neuroscience, 26:1334-1342 (2006)
	AL	D. Sondhi, et al., AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-1 expression compatible with therapy for LINCL, Gene Therapy, 12:1618-1632 (2005)
↓	AM	R.E. Haskell, et al., Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-1 to the mouse central nervous system, Gene Therapy, 10:34-42 (2003)
AS	AN	N.R. Hackett, et al., Safety of direct administration of AAV2 _{ca} hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates, Human Gene Therapy, 16:1484-1503 (2005)

EXAMINER: /Anoop Singh/ DATE CONSIDERED: 10/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.